百济神州 DLL3/CD3 双抗拟纳入优先审评

Insight数据库
Jul 08, 2025

7 月 8 日,CDE 官网显示,百济神州申报的注射用塔拉妥单抗拟纳入优先审评,用于既往接受过至少 2 线治疗(包括含铂化疗)失败的广泛期小细胞肺癌(ES-SCLC)成人患者的治疗。截图来源:CDE 官网塔拉妥单抗是一款由安进公司研发的创新靶向免疫疗法,能够同时结合肿瘤细胞上的 DLL3 蛋白和 T 细胞上的 CD3 蛋白,进而激活 T 细胞来杀伤表达 DLL3 蛋白的肿瘤细胞。2019 年 10...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10